Adefovir adenylate competitive incorporation of viral DNA chain to inhibit DNA polymerase as a DNA chain terminator to terminate the synthesis of the DNA strands, leaving the viral replication is suppressed, but also can induce the endogenous alpha-interference factors, increase vitality and stimulate the immune response of natural killer (NK) cells, the role of a strong anti-HIV, HBV and herpes virus. Adefovir in recent clinical trials, adverse reactions, kidney damage and deserve attention. Current clinical trials dose (once daily) 30 mg (11 patients) and 10 mg (12 patients). Participated in the experiment to 23 after lamivudine can detect HBV DNA in patients. 8 of them were affected renal function after the administration lowered the dose: 6 down from 30 mg to 10 mg.
No comments:
Post a Comment